Kevin Lee1, Alexandra Istl1, Luc Dubois1, Guy DeRose1, Thomas L Forbes1, Daniele Wiseman2, Amol Mujoomdar2, Stewart Kribs2, Adam H Power3. 1. Division of Vascular Surgery, London Health Sciences Centre, Western University, London, Ontario, Canada. 2. Division of Interventional Radiology, London Health Sciences Centre, Western University, London, Ontario, Canada. 3. Division of Vascular Surgery, London Health Sciences Centre, Western University, London, Ontario, Canada adam.power@lhsc.on.ca.
Abstract
PURPOSE: The purpose of this study was to determine whether low fibrinogen levels (fibrinogen level <1.5 g/L) during catheter-directed thrombolysis are associated with an increased bleeding risk. METHODS: A retrospective review was performed on patients undergoing extremity arterial or venous thrombolysis between 2005 and 2013. RESULTS: Patients in the low fibrinogen group were younger (P = .006) and had a higher number of venous occlusive events (P = .004). The low fibrinogen group received a larger dose of tissue plasminogen activator (tPA; P = .009) and had a longer duration of thrombolysis (P = .010). The rates of major bleeding were not significantly different (P = .139). Univariate analysis showed that larger total dose and longer duration of tPA infusion were associated with increased bleeding complications (P < .01 and P = .03). CONCLUSION: A fibrinogen level <1.5 g/L during thrombolysis was not associated with an increased bleeding risk. However, larger dose and longer duration of thrombolysis were associated with increased bleeding risk.
PURPOSE: The purpose of this study was to determine whether low fibrinogen levels (fibrinogen level <1.5 g/L) during catheter-directed thrombolysis are associated with an increased bleeding risk. METHODS: A retrospective review was performed on patients undergoing extremity arterial or venous thrombolysis between 2005 and 2013. RESULTS:Patients in the low fibrinogen group were younger (P = .006) and had a higher number of venous occlusive events (P = .004). The low fibrinogen group received a larger dose of tissue plasminogen activator (tPA; P = .009) and had a longer duration of thrombolysis (P = .010). The rates of major bleeding were not significantly different (P = .139). Univariate analysis showed that larger total dose and longer duration of tPA infusion were associated with increased bleeding complications (P < .01 and P = .03). CONCLUSION: A fibrinogen level <1.5 g/L during thrombolysis was not associated with an increased bleeding risk. However, larger dose and longer duration of thrombolysis were associated with increased bleeding risk.
Authors: Shuai Xiao; Dingbang Hu; Ya Gao; Yang Ai; Sang Luo; Song Chen; Ben Wang; Li Zhou; Yanshan Dong; Yefu Wang Journal: BMC Pharmacol Toxicol Date: 2021-06-26 Impact factor: 2.483